Michelle Vanderpool
Family · Wasilla, AKNPI 1477224426
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 39.8% of the total.
Across 57 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$593
- GSK$234
- Xeris Pharmaceuticals, Inc.$75
- AbbVie$68
- Lilly USA, LLC$63
- Exact Sciences$54
- plus $402 from 15 others
What the payments were for
- Food & beverage$1,47099%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $593 |
| GSK | 9 | $234 |
| Xeris Pharmaceuticals, Inc. | 3 | $75 |
| AbbVie | 3 | $68 |
| Lilly USA, LLC | 3 | $63 |
| Exact Sciences | 2 | $54 |
| Pfizer | 3 | $54 |
| Averitas Pharma Inc. | 2 | $47 |
| Bayer | 2 | $41 |
| Amgen | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Merck | 1 | $25 |
| Mylan Specialty L.p. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Novo Nordisk | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Neurelis, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,490 in reported general payments places this provider in the 80th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $77,950 |
| FarxigaDapagliflozin Propanediol | 47 | $56,345 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $48,015 |
| OzempicSemaglutide | 35 | $45,427 |
| JardianceEmpagliflozin | 47 | $44,121 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $41,815 |
| TrulicityDulaglutide | 28 | $39,139 |
| MounjaroTirzepatide | 26 | $32,863 |
| JanuviaSitagliptin Phosphate | 19 | $27,389 |
| AirsupraAlbuterol Sulfate/Budesonide | 11 | $17,222 |
| Repatha SureclickEvolocumab | 19 | $14,858 |
| MyrbetriqMirabegron | 14 | $13,173 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $12,660 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $8,559 |
| BrilintaTicagrelor | 18 | $5,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Airsupra, Brilinta | $593 | $126,786106 claims |
| PfizerEliquis | $54 | $77,95064 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $63 | $72,00254 claims |
| Novo NordiskOzempic | $18 | $45,42735 claims |
| GSKTrelegy Ellipta | $234 | $41,81530 claims |
| MerckJanuvia | $25 | $27,38919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 315 family providers in Alaska.
Other family in Wasilla
- Kymberli BrockWasilla$5K
- Sarah NielsenWasilla$4K
- Alison ArmourWasilla$4K
- Stephanie McQuillinWasilla$4K
- Liudmila FedorWasilla$4K
- Debby MaloneyWasilla$3K
- Alysa SonnentagWasilla$3K
- Christine BailesWasilla$2K
- Lisa Bouyea-FranciesWasilla$2K
- Kathleen MatthewsWasilla$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.